Transarterial chemoembolization in Barcelona Clinic Liver Cancer Stage 0/A hepatocellular carcinoma.
- Authors
- Kim, Heung Cheol; Suk, Ki Tae; Kim, Dong Joon; Yoon, Jai Hoon; Kim, Yeon Soo; Baik, Gwang Ho; Kim, Jin Bong; Kim, Chang Hoon; Sung, Hotaik; Choi, Jong Young; Han, Kwang Hyub; Park, Seung Ha
- Issue Date
- Jan-2014
- Publisher
- W J G PRESS
- Keywords
- Carcinoma; Hepatocellular; Chemoembolization; Therapeutic; Survival; Stage; Efficacy
- Citation
- WORLD JOURNAL OF GASTROENTEROLOGY, v.20, no.3, pp.745 - 754
- Indexed
- SCIE
SCOPUS
- Journal Title
- WORLD JOURNAL OF GASTROENTEROLOGY
- Volume
- 20
- Number
- 3
- Start Page
- 745
- End Page
- 754
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/160824
- DOI
- 10.3748/wjg.v20.i3.745
- ISSN
- 1007-9327
- Abstract
- Aim: To evaluate the clinical characteristics of patients with Barcelona Clinic Liver Cancer (BCLC) stage 0 and A hepatocellular carcinoma (HCC) after transarterial chemoembolization (TACE). Methods: Between January 2001 and September 2011, 129 patients with BCLC stage 0 and stage A HCC who underwent TACE were retrospectively enrolled. Patient characteristics, routine computed tomography and TACE findings, survival time and 1-, 5-, and 10-year survival rates, risk factors for mortality, and survival rates according to the number of risk factors were assessed. Results: The mean size of HCC tumors was 2.4 ± 1.1 cm, and the mean number of TACE procedures performed was 2.5 ± 2.1. The mean overall survival time and 1-, 5-, and 10-year survival rates were 80.6 ± 4.9 mo and 91%, 63% and 49%, respectively. In the Cox regression analysis, a Child-Pugh score > 5 (P = 0.005, OR = 3.86), presence of arterio-venous shunt (P = 0.032, OR = 4.41), amount of lipiodol used (> 7 mL; P = 0.013, OR = 3.51), and female gender (P = 0.008, OR = 3.47) were risk factors for mortality. The 1-, 5-, and 10-year survival rates according to the number of risk factors present were 96%, 87% and 87% (no risk factors), 89%, 65%, and 35% (1 risk factor), 96%, 48% and unavailable (2 risk factors), and 63%, 17%, and 0% (3 risk factors), respectively (P < 0.001). Conclusion: TACE may be used as curative-intent therapy in patients with BCLC stage 0 and stage A HCC. The Child-Pugh score, arterio-venous shunt, amount of lipiodol used, and gender were related to mortality after TACE.
- Files in This Item
-
Go to Link
- Appears in
Collections - 서울 의과대학 > 서울 내과학교실 > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.